Could early ibrutinib stop CLL before it starts?
NCT ID NCT03207555
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether giving the drug ibrutinib early to people with chronic lymphocytic leukemia (CLL) who have no symptoms but are at high risk for progression could be more effective than waiting. Twenty-three participants took ibrutinib daily for up to 24 months. The goal was to see how many achieved complete or partial remission, and how long they lived without the disease getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ibrutinib (Imbruvica)
What this could lead to
If successful, this could show that starting ibrutinib early in high-risk CLL patients without symptoms delays disease progression and improves outcomes.
What could go wrong
This is a small Phase 2 trial with only 23 participants, so results may not apply to all patients. Ibrutinib has side effects like bleeding, infection, and heart issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASMS STATED AS PRIMARY LYMPHOID HAEMATOPOIETIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States